Search
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigationalCentanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational(IL-6) blockers, and tumor necrosis factor (TNF) inhibitors. … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigationalphosphorylation and recruitment of β-arrestin. … [A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516]
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 奥赛利定Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigationalcell morphology and a risk for transformation to acute myeloid leukemia. … Imetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSynonyms: 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dioneMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnwith a possible increased risk of death outweighing the benefits. … Unfortunately, many patients experience a relapse or develop resistance to these drugs.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Categories: Heterocyclic Compounds, 1-RingGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment
Categories: MATE 1 Substrates, MATE 2 Substrates